Gene therapy can provide cures for life-threatening diseases that do not respond well to other therapies and for acute conditions that rely on complex and expensive life-long medications. This presents a significant opportunity for companies to help people live better lives. The need for speed is paramount as many companies compete for the same indication.
Learn how our integrated approach can help you navigate the twists and turns of viral vector and gene therapy process development and tech transfer all the way through to commercial readiness. This talk will shed light on topics relating to process development for viral vector manufacturing, analytics, and commercial readiness.
In this webinar, you will learn about:
- Process development, analytics, commercial readiness, and related process challenges
- Avoiding costly and time-consuming mistakes in gene therapy process development and tech transfer
- Guidelines to select the right CDMO for your program
Speaker
Ratish Krishnan
MilliporeSigma
Senior Strategy Consultant
Ratish Krishnan is a senior strategy consultant in novel modalities bioprocessing. He has nearly 15 years of bioprocessing experience in vaccine, monoclonal antibodies, and viral vector modalities from pre-clinical to late-stage process characterization, validation, and commercialization activities. Ratish has led process development teams at Novartis and Pfizer prior to his current role where he serves as a global subject matter expert for viral vector manufacturing and provides strategic guidance to stakeholders and key customers. He is active in thought leadership activities at scientific conferences, technical webinars, and key authorship contributions in peer-reviewed articles.
Pharma and biopharma manufacturing
- Viral Vector Upstream Processing
Duration:45min
Language:English
Session 1:presented April 2, 2020
To continue reading please sign in or create an account.
Don't Have An Account?